A carregar...
Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung
BACKGROUND: Lutathera is a (177)Lutetium-labeled somatostatin analog approved for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). Somatostatin receptors are expressed in small cell lung cancer (SCLC). Nivolumab, an anti-PD-1 antibody, may act synergistically with lutathera to g...
Na minha lista:
| Publicado no: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7333915/ https://ncbi.nlm.nih.gov/pubmed/32616557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000980 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|